Illumina Announces New $250 Million Share Repurchase Authorization
News Nov 03, 2015
Illumina has announced that its Board of Directors has authorized the company to repurchase, on a discretionary basis, up to $250 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors.
The company also announced the completion of the existing discretionary authorization of $96 million that was repurchased since the company reported earnings on October 20th.
"This announcement reflects our conviction in Illumina’s long-term strategy and revenue growth trajectory, as we penetrate the many large, untapped market opportunities ahead," said Marc Stapley, Senior Vice President and Chief Financial Officer at Illumina.
Stapley continued, "It is also indicative of our strong financial position, which enables us to opportunistically execute share repurchases to deliver value to our shareholders, while investing in the long-term growth of the business."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.